表紙
市場調查報告書

異位性皮膚炎:全球臨床實驗趨勢

Atopic dermatitis Global Clinical Trials Review, H2, 2019

出版商 GlobalData 商品編碼 246389
出版日期 內容資訊 英文 716 Pages
訂單完成後即時交付
價格
Back to Top
異位性皮膚炎:全球臨床實驗趨勢 Atopic dermatitis Global Clinical Trials Review, H2, 2019
出版日期: 2019年12月02日內容資訊: 英文 716 Pages
簡介

本報告提供異位性皮膚炎相關臨床研究最新趨勢分析,彙整疾病·治療方法概要,及G7及E7各國的臨床實驗狀況,各地區、各階段的進行狀況,有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 主要國家的臨床實驗數量; 中東/非洲地區
    • 主要國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量:異位性皮膚炎臨床實驗數量佔皮膚病臨床實驗數量比率

各期臨床實驗數量: G7各國

G7各國的臨床實驗數量:各期

E7各國的臨床實驗數量:異位性皮膚炎臨床實驗數量佔皮膚病臨床實驗數量比率

各期臨床實驗數量: E7各國

E7各國的臨床實驗數量:各期

各期臨床實驗數量

  • 各期的進展中臨床實驗數量

各進展狀況臨床實驗數量

評估項目臨別床實驗數量

一定期間所採用的受驗人數

贊助商類別的臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - 異位性皮膚炎治療藥

有潛力的藥劑

  • 最新臨床實驗新聞:異位性皮膚炎

臨床實驗簡介的基本資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC5155CTIDB

GlobalData's clinical trial report, "Atopic dermatitis Global Clinical Trials Review, H2, 2019" provides an overview of topic dermatitis clinical trials scenario. This report provides top line data relating to the clinical trials on topic dermatitis . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials 29
  • Prominent Drugs 30
  • Latest Clinical Trials News on Atopic Dermatitis (Atopic Eczema) 31
  • Nov 14, 2019: Dermira presents new scientific research findings from the lebrikizumab program at Leading International Itch Conference 31
  • Nov 12, 2019: XBiotech announces first patient enrolled in placebo-controlled clinical study evaluating its anti-IL-1 therapy Bermekimab in patients with Atopic Dermatitis (Eczema) 31
  • Nov 10, 2019: Nektar Therapeutics presents data from first-in-human phase 1a study on novel T regulatory cell stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology 32
  • Nov 08, 2019: AnaptysBio reports Etokimab ATLAS phase 2b clinical trial in moderate-to-severe atopic dermatitis fails to meet primary endpoint 32
  • Nov 06, 2019: Arena Pharmaceuticals presented new data highlighting the human mass balance and metabolism profile of Etrasimod at AAPS 33
  • Nov 04, 2019: Ichnos Sciences provides update on its Atopic Dermatitis drug candidate ISB 830 33
  • Nov 04, 2019: Ichnos Sciences announces completion of enrollment of phase 2b trial for Investigational Therapy - ISB 830 33
  • Oct 28, 2019: MorphoSys: MOR106 clinical development in atopic dermatitis stopped 34
  • Oct 28, 2019: Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis 34
  • Oct 23, 2019: RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193 35
  • Oct 23, 2019: BTX 1503 acne phase 2 study results presentation 35
  • Oct 23, 2019: AnaptysBio: Promising therapy for common form of eczema identified in early-stage trial 35
  • Oct 22, 2019: ASLAN Pharmaceuticals enrolls first patient in proof-of-concept study for ASLAN004 targeting Atopic Dermatitis 36
  • Oct 17, 2019: Dermira presents data from phase 2b study of Lebrikizumab in patients with Atopic Dermatitis at Fall Clinical Dermatology Conference 37
  • Oct 14, 2019: Pfizer's JAK1 inhibitor performs well in atopic dermatitis 38
  • Oct 10, 2019: Dermira launches Phase III lebrikizumab programme 38
  • Oct 10, 2019: Dermira to present data from phase 2b study of Lebrikizumab in patients with atopic dermatitis at Fall Clinical Dermatology Conference 38
  • Oct 10, 2019: Galderma advances phase 3 clinical study with Nemolizumab in moderate-to-severe atopic dermatitis 39
  • Oct 09, 2019: AbbVie announces new data from Upadacitinib at the 28th European Academy of Dermatology and Venereology (EADV) Congress 39
  • Oct 08, 2019: Innovation Pharmaceuticals cites recent academic literature showing host defense proteins at Cutting-Edge of Medicine for Multiple Diseases 40
  • Oct 08, 2019: Lilly presents on Olumiant at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress 40
  • Oct 07, 2019: Nektar Therapeutics announces initiation of two clinical studies of novel T regulatory cell stimulator NKTR-358 (LY3471851) in patients with psoriasis and atopic dermatitis 41
  • Sep 27, 2019: Pfizer announces positive top-line results from second pivotal phase 3 study of investigational Oral JAK1 candidate, Abrocitinib, in patients Aged 12 and older with moderate to severe Atopic Dermatitis 41
  • Sep 27, 2019: Health Canada approves Dupixent™ as the first biologic for the treatment of adolescents with moderate-to-severe atopic dermatitis 42
  • Sep 17, 2019: Arena pharmaceuticals to present new preclinical atopic dermatitis data for Etrasimod at the European Society for Dermatologic Research Annual Meeting 43
  • Clinical Trial Profile Snapshots 44

Appendix 723

  • Abbreviations 723
  • Definitions 723
  • Research Methodology 724
  • Secondary Research 724
  • About GlobalData 724
  • Contact Us 725
  • Source 725

List of Tables

  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Region, 2019* 8
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 10
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 11
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 12
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, North America, Top Countries, 2019* 13
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019* 14
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 15
  • Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials, G7 Countries (%), 2019* 16
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 17
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 18
  • Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials, E7 Countries (%), 2019* 19
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 20
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 21
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Phase, 2019* 22
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 23
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 24
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 25
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 26
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 27
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 28
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 29
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 30

List of Figures

  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Region (%), 2019* 8
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 10
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 11
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 12
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 13
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019* 14
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 15
  • Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials, G7 Countries (%), 2019* 16
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 17
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 18
  • Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials, E7 Countries (%), 2019* 19
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 20
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 21
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Phase (%), 2019* 22
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 23
  • Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 24
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 25
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 26
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 27
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 28
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 29
  • Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 30
  • GlobalData Methodology 724
Back to Top